Lipoxygenase emerges as a promising antiviral agent against severe fever with thrombocytopenia syndrome Post author:admin Post published: July 20, 2025 Post category:uncategorized Severe fever with thrombocytopenia syndrome (SFTS) was reported in Asia, with a fatality rate that can reach as high as 50%. You Might Also Like UCSF scientists discover less invasive prenatal treatment for Angelman syndrome March 4, 2024 Scientists create light-controlled versions of cholesterol December 15, 2025 PCORI announces $100 million funding for pediatric comparative effectiveness research September 4, 2024
PCORI announces $100 million funding for pediatric comparative effectiveness research September 4, 2024